Acomplia could have some new safety data published as early as today in response to new information relating to potential side effects. It is highly unlikely that the European Medicines Agency will withdraw the drug’s licence but it is likely to issue new warnings over the risks of depression and the potential for suicidal thoughts. We have not had any reports of patients feeling suicidal but as we have said in previous news stories, a few patients have suffered from depression.
As soon as we have any new information, we will publish the information here.